Mavenclad

Cladribine, the active ingredient in Mavenclad, is a purine nucleoside analog presented as 10 mg and 20 mg tablets for oral administration. It is indicated for the treatment of relapsing‑remitting multiple sclerosis and active secondary progressive multiple sclerosis in adult patients by selectively depleting circulating lymphocytes and modulating immune activity.

GNH USA supplies Mavenclad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance across EU and global markets.

Mavenclad (cladribine) is used in disease‑modifying therapy for multiple sclerosis, targeting immune‑mediated disease activity. - Relapsing‑remitting multiple sclerosis: reduces annual relapse rate and slows disability progression. - Active secondary progressive multiple sclerosis: decreases disease activity and may delay worsening of disability. - Adults with multiple sclerosis: provides an intermittent oral dosing option for long‑term disease management.

Cladribine may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate headache reported. - Nausea: transient nausea, often mild. - Fatigue: general tiredness during treatment. - Lymphopenia: reduced lymphocyte counts, usually reversible.

Serious or Rare Side Effects: - Severe infections: opportunistic infections such as herpes zoster. - Malignancy: rare reports of cancer development. - Autoimmune hepatitis: uncommon liver inflammation.

Before prescribing Mavenclad, clinicians should consider several safety measures. - Monitor lymphocyte counts: perform regular blood tests to detect lymphopenia. - Screen for infections: assess for active infections before initiating therapy. - Avoid live vaccines: live attenuated vaccines may be ineffective or unsafe during treatment. - Pregnancy considerations: use only if benefits outweigh risks; discuss with healthcare provider. - Renal function: adjust use in patients with severe renal impairment. - Store at ambient temperature: keep tablets below 25 °C in original packaging, protect from moisture.

Cladribine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Live vaccines: concurrent administration can cause severe infection. - Immunosuppressive agents: combined use may excessively suppress immunity.

Moderate Interactions (Monitor Closely): - Non‑live vaccines: efficacy may be reduced; schedule appropriately. - CYP3A4 modulators: strong inducers or inhibitors may alter cladribine metabolism. - Anticonvulsants: some may affect blood counts; monitor hematology.